Výsledky vyhledávání - "Beatrice Benetti"

2022-RA-956-ESGO Treatment patterns and outcomes after progression on poly-ADP ribose polymerase inhibitor maintenance therapy

Autor: Giulia Tasca, Francesca Stella Mosimann, Beatrice Benetti, Simona Frezzini, Valentina Montan, Christian Zurlo, Fabio Girardi, Valentina Guarneri

Publikováno v: Ovarian cancer.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::79fff5fca3e80d1d4742807963833f03
https://doi.org/10.1136/ijgc-2022-esgo.606

Zobrazit plný text záznamu

Induction chemotherapy with carboplatin and paclitaxel for thymoma in acute respiratory distress due to myasthenia gravis: a case report

Autor: Giovanni Maria Comacchio, Beatrice Benetti, Elisabetta Di Liso, Alice Menichetti, Valentina Guarneri, Federico Rea, Giulia Pasello

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9568265f5e7e887dbf5b7db10a304f50
https://hdl.handle.net/11577/3456223

Zobrazit plný text záznamu

Circulating cytokines as predictors of response to immune checkpoint inhibitors (ICIs) in patients (pts) with melanoma (Mel) and non–small cell lung cancer (NSCLC)

Autor: Giulia Pasello, Aline Sueli Coelho Fabricio, Paola Del Bianco, Adolfo Favaretto, Valentina Salizzato, Luisa Piccin, Fable Zustovich, Costanza De Rossi, Jacopo Pigozzo, Alessio Fabozzi, Beatrice Benetti, Laura Tiozzo Fasiolo, Laura Bonanno, Valentina Guarneri, Gian Luca De Salvo, Dario Palleschi, Massimo Gion, Vanna Chiarion-Sileni

Publikováno v: Journal of Clinical Oncology. 40:2549-2549

2549 Background: ICIs lead to durable response and a significant survival improvement in a limited number of advanced stage Mel and NSCLC pts. The identification of predictive circulating biomarkers could be a promising tool to optimize pts’ select

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13f78de28e5f215517cae5a7a5b40224
https://doi.org/10.1200/jco.2022.40.16_suppl.2549

Zobrazit plný text záznamu

Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of OSE2021 plus docetaxel or OSE2021 plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy

Autor: Federico Cappuzzo, Giulia Pasello, Angelo Delmonte, Lorenza Landi, Beatrice Benetti, Giulio Metro, Mario Rosario D'Andrea, Stefania Gori, Gloria Borra, Francesca Mazzoni, Claudio Verusio, Maria Pagano, Diana Giannarelli, Andrea Vincent Bonetti, Michele Maio, Antonino Scimone, Vincenzo Adamo

Publikováno v: Journal of Clinical Oncology. 40:TPS9140-TPS9140

TPS9140 Background: First line combination of chemotherapy and immune checkpoint inhibitors (ICIs) improves overall survival (OS) compared with chemotherapy alone in non-small cell lung cancer (NSCLC) patients. However, only few options are available

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce4eb370aa56d2f1e8da8b1987520908
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9140

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání